Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

Petros Pharmaceuticals, Inc.

CIK 1815903 PTPI·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Late filing NT 10-K
  2. Finance chief departure 8-K +183d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure Filing comparison

Petros Pharmaceuticals, Inc.'s Chief Financial Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Late filing elevated Filing comparison

Petros Pharmaceuticals, Inc. told the SEC it could not file its annual report on time

(the “Company”) is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), because the Company requires additional time to complete and finalize its financial statements required to be included in the Form 10-K.
Evidence
Days past due date
0
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), because the Company requires additional time to complete and finalize its financial statements required to be included in the Form 10-K.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗